AU2010203446B2 - Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22 - Google Patents

Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22 Download PDF

Info

Publication number
AU2010203446B2
AU2010203446B2 AU2010203446A AU2010203446A AU2010203446B2 AU 2010203446 B2 AU2010203446 B2 AU 2010203446B2 AU 2010203446 A AU2010203446 A AU 2010203446A AU 2010203446 A AU2010203446 A AU 2010203446A AU 2010203446 B2 AU2010203446 B2 AU 2010203446B2
Authority
AU
Australia
Prior art keywords
multiple organ
treatment
organ dysfunction
prevention
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010203446A
Other languages
English (en)
Other versions
AU2010203446A1 (en
Inventor
Yu Liang Huang
Zhi Hua Huang
Qi Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evive Biotechnology Shanghai Ltd
Original Assignee
Evive Biotechnology Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evive Biotechnology Shanghai Ltd filed Critical Evive Biotechnology Shanghai Ltd
Publication of AU2010203446A1 publication Critical patent/AU2010203446A1/en
Application granted granted Critical
Publication of AU2010203446B2 publication Critical patent/AU2010203446B2/en
Assigned to Evive Biotechnology (Shanghai) Ltd reassignment Evive Biotechnology (Shanghai) Ltd Request to Amend Deed and Register Assignors: GENERON (SHANGHAI) CORP.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2010203446A 2009-01-12 2010-01-11 Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22 Ceased AU2010203446B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14413409P 2009-01-12 2009-01-12
US61/144,134 2009-01-12
PCT/US2010/020673 WO2010081112A1 (en) 2009-01-12 2010-01-11 Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22

Publications (2)

Publication Number Publication Date
AU2010203446A1 AU2010203446A1 (en) 2011-07-14
AU2010203446B2 true AU2010203446B2 (en) 2015-12-17

Family

ID=42316862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010203446A Ceased AU2010203446B2 (en) 2009-01-12 2010-01-11 Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22

Country Status (7)

Country Link
US (1) US8956605B2 (enExample)
EP (1) EP2385841B1 (enExample)
JP (1) JP5981141B2 (enExample)
CN (1) CN102348463B (enExample)
AU (1) AU2010203446B2 (enExample)
CA (1) CA2748392C (enExample)
WO (1) WO2010081112A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
EA035645B1 (ru) 2013-03-15 2020-07-21 Дженентек, Инк. ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
CN112007146A (zh) * 2020-09-03 2020-12-01 上海市儿童医院 Il-22在治疗和/或预防脓毒症诱发的肝脏损伤的药物中的用途
US20240033232A1 (en) * 2021-03-10 2024-02-01 Wen Tan New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207943A1 (en) * 1998-05-29 2007-09-06 Human Genome Sciences, Inc. Interleukins-21 and 22
US20080241246A1 (en) * 2006-11-15 2008-10-02 Arteriocyte Inc. Cell-based therapies for treating liver disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US7226591B2 (en) * 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
CN101168049A (zh) * 2007-10-23 2008-04-30 中国人民解放军军事医学科学院基础医学研究所 白介素-22在制备治疗肝病药物中的应用及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207943A1 (en) * 1998-05-29 2007-09-06 Human Genome Sciences, Inc. Interleukins-21 and 22
US20080241246A1 (en) * 2006-11-15 2008-10-02 Arteriocyte Inc. Cell-based therapies for treating liver disease

Also Published As

Publication number Publication date
EP2385841B1 (en) 2016-11-16
US20110268696A1 (en) 2011-11-03
CN102348463B (zh) 2014-05-07
CA2748392A1 (en) 2010-07-15
EP2385841A1 (en) 2011-11-16
US8956605B2 (en) 2015-02-17
JP2012515165A (ja) 2012-07-05
JP5981141B2 (ja) 2016-08-31
WO2010081112A1 (en) 2010-07-15
CA2748392C (en) 2017-06-27
AU2010203446A1 (en) 2011-07-14
CN102348463A (zh) 2012-02-08
EP2385841A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
EP2875826B1 (en) Composition for preventing or treating sepsis
AU2010203446B2 (en) Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
US20090227512A1 (en) Methods and compositions for treating and preventing distal bowel lesions
HU229045B1 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
JP6114186B2 (ja) 組換えヒトｇ−ｃｓｆ二量体およびその神経系疾患の治療における用途
EP2680872B1 (en) Use of pif peptides for treating infections, atherosclerosis and peritonitis
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
US20220339251A1 (en) Compositions and methods for recombinant nerve growth factor
CN103649106B (zh) 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合
JP3266248B2 (ja) 傷害を処置するための方法及び組成物
JP7163547B2 (ja) 新規ペプチドおよびその用途
JP2017517561A (ja) 最適化ハムスターｒｅｇ３ガンマペプチドを利用する糖尿病を有する患者の間でのインスリン非依存性
JP4023863B2 (ja) Ｉｌ−６を含む血清尿酸値低下剤
AU2007226130B2 (en) Use of caspases for the preparation of medicaments
CN102485272A (zh) 重组人Prx-6蛋白在治疗烧烫伤方面的用途
Fang Research Progress and Future Prospects of Three Oncolytic Viruses in the Treatment of Melanoma
US7790155B2 (en) Calbindin-D28K protection against glucocorticoid induced cell death
CN120939206A (zh) Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用
MXPA01012663A (es) Uso de interleucina-11 para tratar el shock hemorragico.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: EVIVE BIOTECHNOLOGY (SHANGHAI) LTD

Free format text: FORMER NAME(S): GENERON (SHANGHAI) CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired